# Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines

> **NCT02303002** · PHASE2 · COMPLETED · sponsor: **Revance Therapeutics, Inc.** · enrollment: 268 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **BIOLOGICAL:** Botulinum Toxin Type A
- **BIOLOGICAL:** Active Comparator botulinum toxin
- **BIOLOGICAL:** Placebo Comparator

## Key facts

- **NCT ID:** NCT02303002
- **Lead sponsor:** Revance Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-12
- **Final completion:** 2016-01
- **Target enrollment:** 268 (ACTUAL)
- **Last updated:** 2016-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02303002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02303002, "Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02303002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*